Neuro Kinetics, Inc. (NKI), the global leader in clinical eye tracking and neural functional assessments, announced today that the United States Patent and Trademark Office (USPTO) recently awarded it three more patents , increasing NKI's patent count to twenty two (22 ).
These new patents augment the company's existing patent portfolio for its I-Portal® clinical eye-tracking technology and strengthen NKI's market-leading number of FDA -cleared medical tests. The study was published in the PLOS one
The new patents are:
- US Patent No. 9,655,515 , "Method of Precision Eye-Tracking Through Use of Iris Edge-Based Landmarks in Eye Geometry." The precise video tracking of eye movements is critical to effective neuro-functional measurements. NKI strengthened its technological leadership in eye tracking with this patent by protecting NKI's unique idea of ??using fixed points on the outer edge of the iris to track eye movements.
- US Patent No. 9,723,981 , "Head Mounted Compact Goggle-Based Video Oculography System with Integral Stimulus Display." NKI's I-PAS ™ (I-Portal Portable Assessment System) integrates head-mounted display that uses goggles to deliver oculomotor testing with clinically sensitive eye tracking. Looking like a virtual reality headset, and just as easy to put on and take off, NKI's engineers were the first to design this innovative, and now patented, highly portable platform.
- US Patent No. 9,730,583 , "Method and Apparatus for Corrective Secondary Saccades Analysis with Video Oculography System for Objective Diagnostic of Traumatic Brain Injury, Internuclear Opthalmopligia, Lateral Pulsion and Progressive Supernuclear Eye Palsey and Glissades." Corrective Saccades, or involuntary second movements of the eyes to center on a target, are a clinically important diagnostic. Once again, NKI's sensitive eye tracking technology allows for new insights and enables NKI to observe, measure and analyze non-obvious components of these Corrective Saccades, which are proving to be important for a wide range of conditions, including concussions.
Howison Schroeder, President and CEO of NKI said, "These new patents represent NKI's continued commitment to innovation and leadership in clinical eye-tracking ." Such innovations are at the core of NKI's objective, neural-functional datasets that place NKI at the forefront of solving the concussion conundrum.
Health care practitioners are eager for a device that can objectively measure, monitor and report acute symptoms of concussions. With the goal of contributing to vestibular and neurotologic diagnoses and monitoring of concussion rehabilitation, NKI has submitted 510 (k) to the US FDA for the clearance of the patented I-PAS ™, for its use as a nystagmograph .
While the use of I-Portal tests for concussion should be considered, the FDA has already cleared other NKI devices that pre-date I-PAS for their use in vestibular testing. Future NKI submissions to the FDA are anticipated for specific use to concussions .
Dr. Alex Kiderman, CFO of Neuro Kinetics said, The possibility of a reliable , highly portable, objective metric for monitoring the progression of concussion and other medical conditions in the near term, bolstered by these patented innovations , is very exciting. "